AstraZeneca PLC (AZN)
162.70
-2.07
(-1.26%)
USD |
NYSE |
Sep 04, 16:00
163.00
+0.30
(+0.18%)
After-Hours: 20:00
AstraZeneca SG&A Expense (TTM) : 585.31M for March 31, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 585.31M |
| December 31, 2025 | 580.07M |
| September 30, 2025 | 568.96M |
| June 30, 2025 | 566.88M |
| March 31, 2025 | 554.19M |
| December 31, 2024 | 553.67M |
| September 30, 2024 | 557.00M |
| June 30, 2024 | 541.00M |
| March 31, 2024 | 540.00M |
| December 31, 2023 | 539.00M |
| September 30, 2023 | 550.00M |
| June 30, 2023 | 547.00M |
| March 31, 2023 | 545.00M |
| December 31, 2022 | 536.00M |
| September 30, 2022 | 504.00M |
| June 30, 2022 | 498.00M |
| March 31, 2022 | 472.00M |
| December 31, 2021 | 446.00M |
| September 30, 2021 | 431.00M |
| June 30, 2021 | 410.00M |
| March 31, 2021 | 411.00M |
| December 31, 2020 | 399.00M |
| September 30, 2020 | 382.00M |
| June 30, 2020 | 371.00M |
| March 31, 2020 | 348.00M |
| Date | Value |
|---|---|
| December 31, 2019 | 339.00M |
| September 30, 2019 | 340.00M |
| June 30, 2019 | 325.00M |
| March 31, 2019 | 328.00M |
| December 31, 2018 | 331.00M |
| September 30, 2018 | 323.00M |
| June 30, 2018 | 326.00M |
| March 31, 2018 | 314.00M |
| December 31, 2017 | 310.00M |
| September 30, 2017 | 308.00M |
| June 30, 2017 | 308.00M |
| March 31, 2017 | 327.00M |
| December 31, 2016 | 326.00M |
| September 30, 2016 | 342.00M |
| June 30, 2016 | 345.00M |
| March 31, 2016 | 338.00M |
| December 31, 2015 | 339.00M |
| September 30, 2015 | 328.00M |
| June 30, 2015 | 336.00M |
| March 31, 2015 | 329.00M |
| December 31, 2014 | 324.00M |
| September 30, 2014 | 3.006B |
| June 30, 2014 | 5.478B |
| March 31, 2014 | 7.964B |
| December 31, 2013 | 10.44B |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| GSK Plc | 12.34B |
| Johnson & Johnson | 25.14B |
| Eli Lilly & Co. | 12.24B |
| Merck & Co., Inc. | 11.14B |
| Novo Nordisk A/S | 10.12B |